Company / Return on Equity (ROE)
Oruka Therapeutics, Inc. Return on Equity (ROE) History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-14.4%
FY2023
5-year range
-72.0% / -14.4%
FY2019-FY2023
Trend
+61.9%
vs FY2022
Sector context
#68 of 190
Health Care
What the data says
Oruka Therapeutics, Inc. reports negative total equity of -14.4% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-14.4% in FY2023 with a 5-year CAGR of +165.5%.
Improved from -20.9% to -14.4% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +57.6pp
- 5-Year Change
- +165.5pp
- 10-Year Change
- -
Sector benchmark
#68 of 190 in Health CareTop 36% of 190This company -14.4% Sector average -50.4%
▼
+71.4% above sector average
Key checks
Key Insights
- In FY2023, return on equity (roe) increased 61.9% year-over-year.
- Currently 36.0pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -14.4% | +61.9% |
| FY2022 | -37.9% | -80.8% |
| FY2021 | -20.9% | +70.9% |
| FY2020 | -72.0% | +45.2% |
| FY2019 | -131.5% | +26.9% |
| FY2018 | -180.0% | -142.9% |
| FY2017 | -74.1% | -146.5% |
| FY2016 | -30.1% | +54.3% |
| FY2015 | -65.7% | -47.6% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026